Page last updated: 2024-09-04

pomalidomide and Stevens-Johnson Syndrome

pomalidomide has been researched along with Stevens-Johnson Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ	1

Trials

1 trial(s) available for pomalidomide and Stevens-Johnson Syndrome

Article	Year
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. The Lancet. Haematology, 2019, Volume: 6, Issue:9 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Multiple Myeloma; Myocarditis; Progression-Free Survival; Proportional Hazards Models; Recurrence; Stevens-Johnson Syndrome; Survival Rate; Thalidomide; Treatment Outcome	2019

Article

Year

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

The Lancet. Haematology, 2019, Volume: 6, Issue:9

Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Multiple Myeloma; Myocarditis; Progression-Free Survival; Proportional Hazards Models; Recurrence; Stevens-Johnson Syndrome; Survival Rate; Thalidomide; Treatment Outcome

2019